According to the latest research by InsightAce Analytic, the global Somatotropin market will be valued at US$ 6.03 Billion in 2021. It is expected to grow with a CAGR of 7.53% during a forecast period of 2022-2030. Growth hormone is a natural hormone secreted by the pituitary gland of the human body. It regulated various complex physiological processes of the body, which mainly include growth and metabolism. It plays a role in achieving normal growth in children and is also helps to regulate lipid, carbohydrate, and protein metabolism in all age groups (childhood & adulthood). The synthetic form of human growth hormone is known as somatropin. Until 1985, the growth hormone is obtained through extraction from cadaveric pituitary glands due to its side effect, it was discontinued, and the first synthetic growth hormone was approved by the U.S. Food Drug Administration in 1985 for the treatment of growth hormone deficiency. It is also approved for the treatment of chronic renal insufficiency, adult growth hormone deficiency, truners syndrome, Prader-Willi syndrome, idiopathic short stature, and Noonan syndrome. It is also an anti-aging therapy yet is not approved for this indication. Much synthetic human growth hormone is now available in the market, which includes Humatrope (Lilly), Nutropin (Genentech), Norditropin (Novo), Genotropin (Pfizer), and Saizen (Merck Serono). As of 2006, the recombinant version of somatropin was launched a ‘Omnitrope’ by Sandoz. Growing demand for somatropin, led by rising growth hormone deficiency cases and advancement in rDNA technology, has boosted the growth of the global somatropin market in the forecast period. Moreover, ongoing clinical trials of somatropin in various therapeutic areas further drive the development of the market. However, stringent regulatory process and complicated manufacturing process are the factors restrain the growth of the global somatropin market.
The global somatropin market is segmented on the basis of application, distribution channel, and geography. On the basis of application, the global somatropin market is further sub-segmented into chronic renal insufficiency, growth hormone deficiency, turners syndrome, Prader-Willi syndrome, idiopathic short stature, and Noonan syndrome. Growth hormone deficiency followed turners syndrome segment is expected to hold a significant share of the market due to an increase in the number of patients suffering from pituitary dysfunction and the effectivity of the somatropin to treat turners syndrome. Based on distribution channels, the global somatropin market is segmented into online pharmacy, hospital pharmacy and retail pharmacy. Hospital pharmacy is a major contributor in terms of revenue to the market as somatropin is available on prescription and increases the number of hospital visits.
At the regional level, the global Somatropin market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In terms of revenue, North America, followed by Europe, is a major contributor to the global somatropin market. This is partly because of increased government initiatives for cost-effective treatment and the rising number of pituitary dysfunction cases. Furthermore, a strong clinical pipeline and increasing research and drug development activities propel the growth of the market in these regions. The Asia Pacific is the third promising revenue contributor, which is expected to grow at a rapid pace in the upcoming year. Countries such as Japan, India, and China are significant contributors to this market and are identified as most lucrative for this market. Emerging and huge population base countries such as China and India offer tremendous market opportunities.
Some of the market players leading the global somatropin market include Sandoz, F. Hoffmann-La Roche AG, Pfizer, Eli Lilly and Company, Novo Nordisk, Merck co., and many more.
